WO2024127317 - TREATING MITOCHONDRIAL DYSFUNCTION WITH MIRNA-485 INHIBITOR
National phase entry is expected:
Publication Number
WO/2024/127317
Publication Date
20.06.2024
International Application No.
PCT/IB2023/062712
International Filing Date
14.12.2023
Title **
[English]
TREATING MITOCHONDRIAL DYSFUNCTION WITH MIRNA-485 INHIBITOR
[French]
TRAITEMENT D'UN DYSFONCTIONNEMENT MITOCHONDRIAL AVEC UN INHIBITEUR DE MIARN-485
Applicants **
BIORCHESTRA CO., LTD.
Inventors
RYU, Jin-Hyeob
KOH, Han Seok
PARK, Young Jin
JANG, Hannah
MIN, Hyun Su
LIM, Yu Na
Priority Data
63/387,455
14.12.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5205 | |
| EPO | Filing, Examination, Granting | 83787 | |
| Japan | Filing, Examination, Granting | 4465 | |
| South Korea | Filing, Examination, Granting | 4769 | |
| USA | Filing, Examination, Granting | 21440 |
Total:
119,666
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to the use of a miR-485 inhibitor to alleviate and/or prevent a mitochondrial function. In some aspects, a miR-485 inhibitor described herein can be used to regulate mitophagy, mitochondrial biogenesis, mitochondrial fission, and/or mitochondrial fusion. The present disclosure also relates to the use of a miR-485 inhibitor to treat a mitochondrial disorder.[French]
La présente invention concerne l'utilisation d'un inhibiteur de miR-485 pour soulager et/ou prévenir une fonction mitochondriale. Selon certains aspects, un inhibiteur de miR-485 décrit dans la présente invention peut être utilisé pour réguler la mitophagie, la biogenèse mitochondriale, la fission mitochondriale et/ou la fusion mitochondriale. La présente invention concerne également l'utilisation d'un inhibiteur de miR-485 pour traiter un trouble mitochondrial.